Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - esomeprazole magnesium, quantity: 20.7 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: diethyl phthalate; macrogol 4000; sodium stearylfumarate; hyprolose; purified talc; microcrystalline cellulose; macrogol 400; povidone; hypromellose phthalate; crospovidone; macrogol 6000; titanium dioxide; hypromellose; iron oxide red; maize starch; sucrose - gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - memantine hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - atorvastatin calcium, quantity: 20.68 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; macrogol 4000; pregelatinised maize starch; activated attapulgite; magnesium stearate; hypromellose; titanium dioxide; microcrystalline cellulose; colloidal anhydrous silica; hyprolose - an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated. hypertensive patients with multiple risk factors for chd which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see actions, clinical trials, prevention of cardiovascular disease) to reduce the risk of nonfatal mi and nonfatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: iron oxide red; lactose monohydrate; sodium bicarbonate; sodium stearylfumarate; pregelatinised maize starch; croscarmellose sodium - ? treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. ,? post mi heart failure ,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sodium stearylfumarate; croscarmellose sodium; sodium bicarbonate; pregelatinised maize starch - ? treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. ,? post mi heart failure ,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 10 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; sodium stearylfumarate; sodium bicarbonate; croscarmellose sodium - ? treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. ,? post mi heart failure ,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: sodium stearylfumarate; iron oxide yellow; sodium bicarbonate; pregelatinised maize starch; croscarmellose sodium; lactose monohydrate - ? treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. ,? post mi heart failure ,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: hypromellose; iron oxide black; macrogol 6000; colloidal anhydrous silica; lactose monohydrate; titanium dioxide; croscarmellose sodium; purified talc; microcrystalline cellulose; hyprolose; iron oxide red; magnesium stearate - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: purified talc; hypromellose; lactose monohydrate; iron oxide red; titanium dioxide; microcrystalline cellulose; croscarmellose sodium; iron oxide yellow; macrogol 6000; hyprolose; magnesium stearate; colloidal anhydrous silica - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; lactose monohydrate; hyprolose; titanium dioxide; croscarmellose sodium; colloidal anhydrous silica; macrogol 6000; purified talc; microcrystalline cellulose; iron oxide red; iron oxide yellow - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.